Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01990677 · ClinicalTrials.gov registry record · NA
Eplerenone for the Treatment of Central Serous Chorioretinopathy
A NA study of Central Serous Chorioretinopathy, sponsored by Wills Eye.
- Completed
- Registry status
- NA
- Development phase
- 108
- Enrollment target
- 10
- Study locations
NCT01990677: Completed NA study of Central Serous Chorioretinopathy, sponsored by Wills Eye.
NCT01990677 is a NA study of Central Serous Chorioretinopathy that has completed, run by Wills Eye. The registered enrollment target is 108 participants, above the 68-participant average among 5 other Central Serous Chorioretinopathy trials with a reported enrollment target (59% higher). The trial reports 10 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01990677, a NA study of Central Serous Chorioretinopathy, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- NA
- Development phase
- 108 participants
- Enrollment target
- 10
- Study locations
Study Summary
To test the effect oral eplerenone versus placebo in patients with central serious chorioretinopathy .
Primary Outcome
Mean change in maximal subretinal fluid height based on spectral domain OCT from baseline to month 2 in chronic central serous chorioretinopathy (CSCR) patients receiving placebo versus eplerenone.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG 25mg Eplerenone
Study Locations (10)
Pennsylvania
- Mid Atlantic Retina - Bala-Cynwyd
- Mid Atlantic Retina - Bethlehem
- Mid Atlantic Retina - Huntingdon Valley
- Mid Atlantic Retina - Lansdale
- Mid Atlantic Retina - New Wilmington
- Mid Atlantic Retina - Newtown Square
- Mid Atlantic Retina - Plymouth Meeting
New Jersey
- Mid Atlantic Retina - Cherry Hill
- Mid Atlantic Retina - Marlton
- Mid Atlantic Retina - Mays Landing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2013-10 |
| Est. Completion | 2015-05 |
| Phase | NA |
What the finished NCT01990677 record still lists
NCT01990677 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, above the 68-participant average among 5 other Central Serous Chorioretinopathy trials with a reported enrollment target (59% higher).
The record links to 1 condition, with Central Serous Chorioretinopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01990677 lists 10 locations in 2 states (Pennsylvania, New Jersey).
Frequently Asked Questions
What is clinical trial NCT01990677 about?
NCT01990677 is a clinical study titled "Eplerenone for the Treatment of Central Serous Chorioretinopathy". To test the effect oral eplerenone versus placebo in patients with central serious chorioretinopathy .
What is the current status of trial NCT01990677?
This trial is currently completed. It is a NA study. The enrollment target is 108 participants. The study started on 2013-10. Estimated completion is 2015-05.
What conditions does trial NCT01990677 study?
This clinical trial studies the following conditions: Central Serous Chorioretinopathy.
What interventions are being tested in trial NCT01990677?
The interventions under investigation include: Placebo (DRUG), 25mg Eplerenone (DRUG).
Who is sponsoring clinical trial NCT01990677?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01990677 being conducted?
This trial has 10 study locations across New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Serous Chorioretinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
OCT in Rare Chorioretinal Diseases
RECRUITING
-
Short-Term Oral Mifepristone for Central Serous Chorioretinopathy
COMPLETED · Phase 2
-
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
COMPLETED
-
The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy
COMPLETED · Phase 2
-
Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia